CBMG

AcronymDefinition
CBMGCell Biology and Molecular Genetics (academic program; University of Maryland; College Park, MD)
CBMGCognitive Brain Mapping Group (Northwestern University; Evanston, IL)
CBMGCoal Bed Methane Gas
CBMGCorporate Benefit Management Group (Memphis, TN)
References in periodicals archive ?
CBMG's allogeneic adipose-derived mesenchymal progenitor cell (haMPC) AlloJoin product is an off-the-shelf stem cell therapy developed completely in-house by CBMG over the past 7 years.
CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG's GMP facilities in Shanghai, Wuxi and Beijing.
US financial services provider EastBridge Investment Group Corp (PINK:EBIG) said it had agreed to tie up with translational medicine firm Cellular Biomedicine Group Inc (CBMG).
Jie Mingxun, PetroChina CBMG's President, said the 4 bcm goal would be from self-financed projects.
The current chairman and chief executive of CBMG, Steve Liu, will also lead the enlarged entity as such, while EastBridge's own chairman and CEO Keith Wong will act as chief business development officer and board director.
CBMG has signed a nonbinding letter of intent regarding the use of GE Healthcare's platform.
A joint laboratory within CBMG's new Shanghai Zhangjiang GMP-facility will be established and dedicated to developing a functionally integrated and automated immunotherapy cell preparation system.
(CBMG) said the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the company $2.29 million to support preclinical studies of AlloJoin, an "off-the-shelf" allogeneic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis in the U.S.
15 November 2012 - US financial services provider EastBridge Investment Group Corp (PINK:EBIG) said it had agreed to tie up with translational medicine firm Cellular Biomedicine Group Inc (CBMG).
(CBMG) said the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the company $2.29 million to support preclinical studies of AlloJoin, an "off-the-shelf allogeneic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis in the U.S.